Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

One-year data suggest allogeneic stem cell-derived islet-cell therapy could become a future option for those with type 1 ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...